DDN News.....
MANF publishes data in Molecular Neurobiology
March 2018
SAN FRANCISCO—MANF Therapeutics, the wholly owned subsidiary of Amarantus Bioscience Holdings Inc., recently published research detailing preclinical work related to mesencephalic astrocyte-derived neurotrophic factor (MANF), which the company is advancing for the treatment of orphan ophthalmological disorders, glaucoma and Parkinson’s disease. The paper in question, “Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats,” was published in Molecular Neurobiology. One week following MANF treatment, an increased release of dopamine was seen in rat models as well as increased dopamine turnover in the rat striatum in response to stimulus. Existing approved drugs for Parkinson’s disease tend to target dopamine replacement, while disease-modifying drugs such as neurotrophic factors generally focus on rescuing dopaminergic neurons. A treatment such as MANF that could encapsulate both approaches could offer a much more effective option for Parkinson’s patients.
Market Data 
Markets 
AI
